β-Glucan – from Food Supplement to a Licensed Drug

by | Sep 28, 2018 | Glucans

J Cell Sci Ther 2015 – β-Glucan – from Food Supplement to a Licensed Drug.  CONCLUSION:  All these new findings mentioned above open the window for β-glucan to become a licensed drug. In addition to effects in anti-infectious and anti-cancer immunity, novel...

A Randomized, Open-Label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of BTH1677 (1,3–1,6 Beta Glucan; Imprime PGG) In Combination with Cetuximab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.

by | Sep 28, 2018 | Cancer, Immunotherapy

Invest New Drugs 2017 – Thomas, M., Sadjadian, P., Kollmeier, J., Lowe, J., Mattson, P., Trout, J., . . . Schneller, F., III. (2017, March 1). A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta...

β-Glucan – Is the Current Research Relevant?

by | Sep 28, 2018 | Cancer, Glucans

International Clinical Pathology Journal 2017 —Vetvicka, Vaclav, and Jana Vetvickova. “Β-Glucan – Is the Current Research Relevant?”. International Clinical Pathology Journal4.2 (2017): 89.  This article focuses on the need for more research with Beta Glucan both on...